查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1360319

细胞和基因治疗製造市场（治疗类型：细胞治疗和基因治疗；产品类型：消耗品、设备和软体）- 2023-2031 年全球产业分析、规模、份额、成长、趋势和预测

Cell and Gene Therapy Manufacturing Market (Therapy Type: Cell Therapy and Gene Therapy; Product Type: Consumables, Equipment, and Software) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 284 Pages | 商品交期: 2-10个工作天内

价格

细胞和基因治疗製造市场 - 报告范围

TMR 关于全球细胞和基因治疗製造市场的报告研究了过去以及当前的成长趋势和机会，以获得 2023 年至 2031 年预测期内市场指标的宝贵见解。该报告提供了全球细胞的收入2017-2031年期间基因治疗製造市场，考虑2023年为基准年，2031年为预测年。该报告也提供了2023年至2031年全球细胞和基因治疗製造市场的年复合成长率（CAGR%）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解细胞和基因治疗製造市场。

市场概况
2023年市场价值 11 亿美元
2031 年市场价值 88 亿美元
复合年增长率 25.2%

该报告深入研究了全球细胞和基因治疗製造市场的竞争格局。全球细胞和基因治疗製造市场的主要参与者已经确定，并且每个参与者都根据各种属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球细胞和基因治疗製造市场参与者的属性。

目录

第一章：前言

第 2 章：假设与研究方法

第 3 章：执行摘要：细胞与基因治疗製造市场

第 4 章：市场概览

  • 介绍
  • 概述
  • 市场动态
  • 2017-2031年细胞与基因治疗製造市场分析与预测

第 5 章：关键见解

  • 技术进步
  • 按地区/全球分類的报销方案
  • 按地区/全球分類的监管情景
  • 全球主要国家的疾病盛行率和发生率
  • COVID-19 大流行对产业的影响（价值炼和短期/中期/长期影响）

第 6 章：细胞与基因治疗製造市场分析与预测：依治疗类型

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依治疗类型，2017-2031
    • 细胞疗法
      • 同种异体
        • 间质干细胞
        • T细胞
        • 诱导性多能干细胞
        • 自然杀手细胞
        • 造血干细胞
        • 其他的
      • 自体
        • T细胞
        • 造血干细胞
        • 间质干细胞
        • 自然杀手细胞
        • 其他的
    • 基因治疗
      • 病毒载体
        • 慢病毒载体
        • 腺相关病毒载体
        • 其他病毒载体
      • 非病毒载体
        • 电穿孔
        • 其他非病毒载体
  • 市场吸引力分析：按治疗类型

第 7 章：细胞与基因治疗製造市场分析与预测：依产品类型

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依产品类型，2017-2031
    • 耗材
    • 装置
      • 细胞加工设备
      • 免洗设备
      • 其他设备
    • 软体与系统
  • 市场吸引力分析：按产品类型

第 8 章：细胞与基因治疗製造市场分析与预测：按技术分类

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依技术分类，2017-2031
    • 细胞培养与扩增
    • 病毒载体生产
    • 细胞分选和纯化
    • 基因编辑
    • 其他的
  • 市场吸引力分析：依技术分类

第 9 章：细胞与基因治疗製造市场分析与预测：按适应症分类

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依指标划分，2017-2031
    • 肿瘤疾病
    • 心血管疾病
    • 骨科疾病
    • 传染病
    • 其他的
  • 市场吸引力分析：依指标分类

第 10 章：细胞与基因治疗製造市场分析与预测：按最终用户

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：按最终用户，2017-2031
    • 製药与生物技术公司
    • 合约製造组织 (CMO)
  • 市场吸引力分析：按最终用户

第 11 章：细胞与基因治疗製造市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2017-2031
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：按地区

第 12 章：北美细胞与基因治疗製造市场分析与预测

第 13 章：欧洲细胞与基因治疗製造市场分析与预测

第 14 章：亚太地区细胞与基因治疗製造市场分析与预测

第 15 章：拉丁美洲细胞与基因治疗製造市场分析与预测

第 16 章：中东和非洲细胞和基因治疗製造市场分析与预测

第17章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：依公司划分（2022 年）
  • 公司简介
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • Bio-Techne Corporation
    • Danaher Corporation
    • General Electric Company (GE Healthcare)
    • Getinge AB
    • Lonza Group Ltd.
    • Merck KGaA
    • Sartorius AG (Sartorius Stedim Biotech SA)
    • Thermo Fisher Scientific Inc.
    • MaxCyte
    • Fresenius Medical Care AG & Co. KGaA
Product Code: TMRGL85808

Cell and Gene Therapy Manufacturing Market - Scope of Report

TMR's report on the global cell and gene therapy manufacturing market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global cell and gene therapy manufacturing market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cell and gene therapy manufacturing market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the cell and gene therapy manufacturing market.

Market Snapshot
Market Value in 2023US$ 1.1 Bn
Market Value in 2031US$ 8.8 Bn
CAGR25.2%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cell and gene therapy manufacturing market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cell and gene therapy manufacturing market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cell and gene therapy manufacturing market.

The report delves into the competitive landscape of the global cell and gene therapy manufacturing market. Key players operating in the global cell and gene therapy manufacturing market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cell and gene therapy manufacturing market profiled in this report.

Key Questions Answered in Global Cell and Gene Therapy Manufacturing Market Report:

  • What is the sales/revenue generated by cell and gene therapy manufacturing across all regions during the forecast period?
  • What are the opportunities in the global cell and gene therapy manufacturing market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Cell and Gene Therapy Manufacturing Market - Research Objectives and Research Approach

The comprehensive report on the global cell and gene therapy manufacturing market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global cell and gene therapy manufacturing market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cell and gene therapy manufacturing market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Cell and Gene Therapy Manufacturing Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Technological Advancements
  • 5.2. Reimbursement Scenario by Region/Globally
  • 5.3. Regulatory Scenario by Region/globally
  • 5.4. Disease Prevalence & Incidence Rate Globally With Key Countries
  • 5.5. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

6. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Therapy Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Therapy Type, 2017-2031
    • 6.3.1. Cell Therapy
      • 6.3.1.1. Allogeneic
        • 6.3.1.1.1. Mesenchymal Stem Cells
        • 6.3.1.1.2. T-cells
        • 6.3.1.1.3. Induced Pluripotent Stem Cells
        • 6.3.1.1.4. Natural Killer Cells
        • 6.3.1.1.5. Hematopoietic Stem Cells
        • 6.3.1.1.6. Others
      • 6.3.1.2. Autologous
        • 6.3.1.2.1. T-cells
        • 6.3.1.2.2. Hematopoietic Stem Cells
        • 6.3.1.2.3. Mesenchymal Stem Cells
        • 6.3.1.2.4. Natural Killer Cells
        • 6.3.1.2.5. Others
    • 6.3.2. Gene Therapy
      • 6.3.2.1. Viral Vector
        • 6.3.2.1.1. Lentiviral Vector
        • 6.3.2.1.2. Adeno-associated Virus Vectors
        • 6.3.2.1.3. Other Viral Vectors
      • 6.3.2.2. Non-viral Vector
        • 6.3.2.2.1. Electroporation
        • 6.3.2.2.2. Other Non-viral Vectors
  • 6.4. Market Attractiveness Analysis, by Therapy Type

7. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Product Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Product Type, 2017-2031
    • 7.3.1. Consumables
    • 7.3.2. Equipment
      • 7.3.2.1. Cell Processing Equipment
      • 7.3.2.2. Single-use Equipment
      • 7.3.2.3. Other Equipment
    • 7.3.3. Software & Systems
  • 7.4. Market Attractiveness Analysis, by Product Type

8. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Technology

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Technology, 2017-2031
    • 8.3.1. Cell Culture & Expansion
    • 8.3.2. Viral Vector Production
    • 8.3.3. Cell Sorting & Purification
    • 8.3.4. Gene Editing
    • 8.3.5. Others
  • 8.4. Market Attractiveness Analysis, by Technology

9. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Indication

  • 9.1. Introduction & Definition
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Indication, 2017-2031
    • 9.3.1. Oncology Disease
    • 9.3.2. Cardiovascular Disease
    • 9.3.3. Orthopedic Disease
    • 9.3.4. Infectious Disease
    • 9.3.5. Others
  • 9.4. Market Attractiveness Analysis, by Indication

10. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by End-user

  • 10.1. Introduction & Definition
  • 10.2. Key Findings/Developments
  • 10.3. Market Value Forecast, by End-user, 2017-2031
    • 10.3.1. Pharmaceutical & Biotechnology Companies
    • 10.3.2. Contract Manufacturing Organizations (CMOs)
  • 10.4. Market Attractiveness Analysis, by End-user

11. Cell and Gene Therapy Manufacturing Market Analysis and Forecast, by Region

  • 11.1. Key Findings
  • 11.2. Market Value Forecast, by Region, 2017-2031
    • 11.2.1. North America
    • 11.2.2. Europe
    • 11.2.3. Asia Pacific
    • 11.2.4. Latin America
    • 11.2.5. Middle East & Africa
  • 11.3. Market Attractiveness Analysis, by Region

12. North America Cell and Gene Therapy Manufacturing Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Therapy Type, 2017-2031
    • 12.2.1. Cell Therapy
      • 12.2.1.1. Allogeneic
        • 12.2.1.1.1. Mesenchymal Stem Cells
        • 12.2.1.1.2. T-cells
        • 12.2.1.1.3. Induced Pluripotent Stem Cells
        • 12.2.1.1.4. Natural Killer Cells
        • 12.2.1.1.5. Hematopoietic Stem Cells
        • 12.2.1.1.6. Others
      • 12.2.1.2. Autologous
        • 12.2.1.2.1. T-cells
        • 12.2.1.2.2. Hematopoietic Stem Cells
        • 12.2.1.2.3. Mesenchymal Stem Cells
        • 12.2.1.2.4. Natural Killer Cells
        • 12.2.1.2.5. Others
    • 12.2.2. Gene Therapy
      • 12.2.2.1. Viral Vector
        • 12.2.2.1.1. Lentiviral Vector
        • 12.2.2.1.2. Adeno-associated Virus Vectors
        • 12.2.2.1.3. Other Viral Vectors
      • 12.2.2.2. Non-viral Vector
        • 12.2.2.2.1. Electroporation
        • 12.2.2.2.2. Other Non-viral Vectors
  • 12.3. Market Value Forecast, by Product Type, 2017-2031
    • 12.3.1. Consumables
    • 12.3.2. Equipment
      • 12.3.2.1. Cell Processing Equipment
      • 12.3.2.2. Single-use Equipment
      • 12.3.2.3. Other Equipment
    • 12.3.3. Software & Systems
  • 12.4. Market Value Forecast, by Technology, 2017-2031
    • 12.4.1. Cell Culture & Expansion
    • 12.4.2. Viral Vector Production
    • 12.4.3. Cell Sorting & Purification
    • 12.4.4. Gene Editing
    • 12.4.5. Others
  • 12.5. Market Value Forecast, by Indication, 2017-2031
    • 12.5.1. Oncology Disease
    • 12.5.2. Cardiovascular Disease
    • 12.5.3. Orthopedic Disease
    • 12.5.4. Infectious Disease
    • 12.5.5. Others
  • 12.6. Market Value Forecast, by End-user, 2017-2031
    • 12.6.1. Pharmaceutical & Biotechnology Companies
    • 12.6.2. Contract Manufacturing Organizations (CMOs)
  • 12.7. Market Value Forecast, by Country, 2017-2031
    • 12.7.1. U.S.
    • 12.7.2. Canada
  • 12.8. Market Attractiveness Analysis
    • 12.8.1. By Therapy Type
    • 12.8.2. By Product Type
    • 12.8.3. By Technology
    • 12.8.4. By Indication
    • 12.8.5. By End-user
    • 12.8.6. By Country

13. Europe Cell and Gene Therapy Manufacturing Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Therapy Type, 2017-2031
    • 13.2.1. Cell Therapy
      • 13.2.1.1. Allogeneic
        • 13.2.1.1.1. Mesenchymal Stem Cells
        • 13.2.1.1.2. T-cells
        • 13.2.1.1.3. Induced Pluripotent Stem Cells
        • 13.2.1.1.4. Natural Killer Cells
        • 13.2.1.1.5. Hematopoietic Stem Cells
        • 13.2.1.1.6. Others
      • 13.2.1.2. Autologous
        • 13.2.1.2.1. T-cells
        • 13.2.1.2.2. Hematopoietic Stem Cells
        • 13.2.1.2.3. Mesenchymal Stem Cells
        • 13.2.1.2.4. Natural Killer Cells
        • 13.2.1.2.5. Others
    • 13.2.2. Gene Therapy
      • 13.2.2.1. Viral Vector
        • 13.2.2.1.1. Lentiviral Vector
        • 13.2.2.1.2. Adeno-associated Virus Vectors
        • 13.2.2.1.3. Other Viral Vectors
      • 13.2.2.2. Non-viral Vector
        • 13.2.2.2.1. Electroporation
        • 13.2.2.2.2. Other Non-viral Vectors
  • 13.3. Market Value Forecast, by Product Type, 2017-2031
    • 13.3.1. Consumables
    • 13.3.2. Equipment
      • 13.3.2.1. Cell Processing Equipment
      • 13.3.2.2. Single-use Equipment
      • 13.3.2.3. Other Equipment
    • 13.3.3. Software & Systems
  • 13.4. Market Value Forecast, by Technology, 2017-2031
    • 13.4.1. Cell Culture & Expansion
    • 13.4.2. Viral Vector Production
    • 13.4.3. Cell Sorting & Purification
    • 13.4.4. Gene Editing
    • 13.4.5. Others
  • 13.5. Market Value Forecast, by Indication, 2017-2031
    • 13.5.1. Oncology Disease
    • 13.5.2. Cardiovascular Disease
    • 13.5.3. Orthopedic Disease
    • 13.5.4. Infectious Disease
    • 13.5.5. Others
  • 13.6. Market Value Forecast, by End-user, 2017-2031
    • 13.6.1. Pharmaceutical & Biotechnology Companies
    • 13.6.2. Contract Manufacturing Organizations (CMOs)
  • 13.7. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.7.1. Germany
    • 13.7.2. U.K.
    • 13.7.3. France
    • 13.7.4. Italy
    • 13.7.5. Spain
    • 13.7.6. Rest of Europe
  • 13.8. Market Attractiveness Analysis
    • 13.8.1. By Therapy Type
    • 13.8.2. By Product Type
    • 13.8.3. By Technology
    • 13.8.4. By Indication
    • 13.8.5. By End-user
    • 13.8.6. By Country/Sub-region

14. Asia Pacific Cell and Gene Therapy Manufacturing Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Therapy Type, 2017-2031
    • 14.2.1. Cell Therapy
      • 14.2.1.1. Allogeneic
        • 14.2.1.1.1. Mesenchymal Stem Cells
        • 14.2.1.1.2. T-cells
        • 14.2.1.1.3. Induced Pluripotent Stem Cells
        • 14.2.1.1.4. Natural Killer Cells
        • 14.2.1.1.5. Hematopoietic Stem Cells
        • 14.2.1.1.6. Others
      • 14.2.1.2. Autologous
        • 14.2.1.2.1. T-cells
        • 14.2.1.2.2. Hematopoietic Stem Cells
        • 14.2.1.2.3. Mesenchymal Stem Cells
        • 14.2.1.2.4. Natural Killer Cells
        • 14.2.1.2.5. Others
    • 14.2.2. Gene Therapy
      • 14.2.2.1. Viral Vector
        • 14.2.2.1.1. Lentiviral Vector
        • 14.2.2.1.2. Adeno-associated Virus Vectors
        • 14.2.2.1.3. Other Viral Vectors
      • 14.2.2.2. Non-viral Vector
        • 14.2.2.2.1. Electroporation
        • 14.2.2.2.2. Other Non-viral Vectors
  • 14.3. Market Value Forecast, by Product Type, 2017-2031
    • 14.3.1. Consumables
    • 14.3.2. Equipment
      • 14.3.2.1. Cell Processing Equipment
      • 14.3.2.2. Single-use Equipment
      • 14.3.2.3. Other Equipment
    • 14.3.3. Software & Systems
  • 14.4. Market Value Forecast, by Technology, 2017-2031
    • 14.4.1. Cell Culture & Expansion
    • 14.4.2. Viral Vector Production
    • 14.4.3. Cell Sorting & Purification
    • 14.4.4. Gene Editing
    • 14.4.5. Others
  • 14.5. Market Value Forecast, by Indication, 2017-2031
    • 14.5.1. Oncology Disease
    • 14.5.2. Cardiovascular Disease
    • 14.5.3. Orthopedic Disease
    • 14.5.4. Infectious Disease
    • 14.5.5. Others
  • 14.6. Market Value Forecast, by End-user, 2017-2031
    • 14.6.1. Pharmaceutical & Biotechnology Companies
    • 14.6.2. Contract Manufacturing Organizations (CMOs)
  • 14.7. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.7.1. China
    • 14.7.2. Japan
    • 14.7.3. India
    • 14.7.4. Australia & New Zealand
    • 14.7.5. Rest of Asia Pacific
  • 14.8. Market Attractiveness Analysis
    • 14.8.1. By Therapy Type
    • 14.8.2. By Product Type
    • 14.8.3. By Technology
    • 14.8.4. By Indication
    • 14.8.5. By End-user
    • 14.8.6. By Country/Sub-region

15. Latin America Cell and Gene Therapy Manufacturing Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Therapy Type, 2017-2031
    • 15.2.1. Cell Therapy
      • 15.2.1.1. Allogeneic
        • 15.2.1.1.1. Mesenchymal Stem Cells
        • 15.2.1.1.2. T-cells
        • 15.2.1.1.3. Induced Pluripotent Stem Cells
        • 15.2.1.1.4. Natural Killer Cells
        • 15.2.1.1.5. Hematopoietic Stem Cells
        • 15.2.1.1.6. Others
      • 15.2.1.2. Autologous
        • 15.2.1.2.1. T-cells
        • 15.2.1.2.2. Hematopoietic Stem Cells
        • 15.2.1.2.3. Mesenchymal Stem Cells
        • 15.2.1.2.4. Natural Killer Cells
        • 15.2.1.2.5. Others
    • 15.2.2. Gene Therapy
      • 15.2.2.1. Viral Vector
        • 15.2.2.1.1. Lentiviral Vector
        • 15.2.2.1.2. Adeno-associated Virus Vectors
        • 15.2.2.1.3. Other Viral Vectors
      • 15.2.2.2. Non-viral Vector
        • 15.2.2.2.1. Electroporation
        • 15.2.2.2.2. Other Non-viral Vectors
  • 15.3. Market Value Forecast, by Product Type, 2017-2031
    • 15.3.1. Consumables
    • 15.3.2. Equipment
      • 15.3.2.1. Cell Processing Equipment
      • 15.3.2.2. Single-use Equipment
      • 15.3.2.3. Other Equipment
    • 15.3.3. Software & Systems
  • 15.4. Market Value Forecast, by Technology, 2017-2031
    • 15.4.1. Cell Culture & Expansion
    • 15.4.2. Viral Vector Production
    • 15.4.3. Cell Sorting & Purification
    • 15.4.4. Gene Editing
    • 15.4.5. Others
  • 15.5. Market Value Forecast, by Indication, 2017-2031
    • 15.5.1. Oncology Disease
    • 15.5.2. Cardiovascular Disease
    • 15.5.3. Orthopedic Disease
    • 15.5.4. Infectious Disease
    • 15.5.5. Others
  • 15.6. Market Value Forecast, by End-user, 2017-2031
    • 15.6.1. Pharmaceutical & Biotechnology Companies
    • 15.6.2. Contract Manufacturing Organizations (CMOs)
  • 15.7. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.7.1. Brazil
    • 15.7.2. Mexico
    • 15.7.3. Rest of Latin America
  • 15.8. Market Attractiveness Analysis
    • 15.8.1. By Therapy Type
    • 15.8.2. By Product Type
    • 15.8.3. By Technology
    • 15.8.4. By Indication
    • 15.8.5. By End-user
    • 15.8.6. By Country/Sub-region

16. Middle East & Africa Cell and Gene Therapy Manufacturing Market Analysis and Forecast

  • 16.1. Introduction
    • 16.1.1. Key Findings
  • 16.2. Market Value Forecast, by Therapy Type, 2017-2031
    • 16.2.1. Cell Therapy
      • 16.2.1.1. Allogeneic
        • 16.2.1.1.1. Mesenchymal Stem Cells
        • 16.2.1.1.2. T-cells
        • 16.2.1.1.3. Induced Pluripotent Stem Cells
        • 16.2.1.1.4. Natural Killer Cells
        • 16.2.1.1.5. Hematopoietic Stem Cells
        • 16.2.1.1.6. Others
      • 16.2.1.2. Autologous
        • 16.2.1.2.1. T-cells
        • 16.2.1.2.2. Hematopoietic Stem Cells
        • 16.2.1.2.3. Mesenchymal Stem Cells
        • 16.2.1.2.4. Natural Killer Cells
        • 16.2.1.2.5. Others
    • 16.2.2. Gene Therapy
      • 16.2.2.1. Viral Vector
        • 16.2.2.1.1. Lentiviral Vector
        • 16.2.2.1.2. Adeno-associated Virus Vectors
        • 16.2.2.1.3. Other Viral Vectors
      • 16.2.2.2. Non-viral Vector
        • 16.2.2.2.1. Electroporation
        • 16.2.2.2.2. Other Non-viral Vectors
  • 16.3. Market Value Forecast, by Product Type, 2017-2031
    • 16.3.1. Consumables
    • 16.3.2. Equipment
      • 16.3.2.1. Cell Processing Equipment
      • 16.3.2.2. Single-use Equipment
      • 16.3.2.3. Other Equipment
    • 16.3.3. Software & Systems
  • 16.4. Market Value Forecast, by Technology, 2017-2031
    • 16.4.1. Cell Culture & Expansion
    • 16.4.2. Viral Vector Production
    • 16.4.3. Cell Sorting & Purification
    • 16.4.4. Gene Editing
    • 16.4.5. Others
  • 16.5. Market Value Forecast, by Indication, 2017-2031
    • 16.5.1. Oncology Disease
    • 16.5.2. Cardiovascular Disease
    • 16.5.3. Orthopedic Disease
    • 16.5.4. Infectious Disease
    • 16.5.5. Others
  • 16.6. Market Value Forecast, by End-user, 2017-2031
    • 16.6.1. Pharmaceutical & Biotechnology Companies
    • 16.6.2. Contract Manufacturing Organizations (CMOs)
  • 16.7. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 16.7.1. GCC Countries
    • 16.7.2. South Africa
    • 16.7.3. Rest of Middle East & Africa
  • 16.8. Market Attractiveness Analysis
    • 16.8.1. By Therapy Type
    • 16.8.2. By Product Type
    • 16.8.3. By Technology
    • 16.8.4. By Indication
    • 16.8.5. By End-user
    • 16.8.6. By Country/Sub-region

17. Competition Landscape

  • 17.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 17.2. Market Share Analysis, by Company (2022)
  • 17.3. Company Profiles
    • 17.3.1. Becton, Dickinson and Company
      • 17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.1.2. Product Portfolio
      • 17.3.1.3. Financial Overview
      • 17.3.1.4. SWOT Analysis
      • 17.3.1.5. Strategic Overview
    • 17.3.2. Bio-Rad Laboratories, Inc.
      • 17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.2.2. Product Portfolio
      • 17.3.2.3. Financial Overview
      • 17.3.2.4. SWOT Analysis
      • 17.3.2.5. Strategic Overview
    • 17.3.3. Bio-Techne Corporation
      • 17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.3.2. Product Portfolio
      • 17.3.3.3. Financial Overview
      • 17.3.3.4. SWOT Analysis
      • 17.3.3.5. Strategic Overview
    • 17.3.4. Danaher Corporation
      • 17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.4.2. Product Portfolio
      • 17.3.4.3. Financial Overview
      • 17.3.4.4. SWOT Analysis
      • 17.3.4.5. Strategic Overview
    • 17.3.5. General Electric Company (GE Healthcare)
      • 17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.5.2. Product Portfolio
      • 17.3.5.3. Financial Overview
      • 17.3.5.4. SWOT Analysis
      • 17.3.5.5. Strategic Overview
    • 17.3.6. Getinge AB
      • 17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.6.2. Product Portfolio
      • 17.3.6.3. Financial Overview
      • 17.3.6.4. SWOT Analysis
      • 17.3.6.5. Strategic Overview
    • 17.3.7. Lonza Group Ltd.
      • 17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.7.2. Product Portfolio
      • 17.3.7.3. Financial Overview
      • 17.3.7.4. SWOT Analysis
      • 17.3.7.5. Strategic Overview
    • 17.3.8. Merck KGaA
      • 17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.8.2. Product Portfolio
      • 17.3.8.3. Financial Overview
      • 17.3.8.4. SWOT Analysis
      • 17.3.8.5. Strategic Overview
    • 17.3.9. Sartorius AG (Sartorius Stedim Biotech S.A.)
      • 17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.9.2. Product Portfolio
      • 17.3.9.3. Financial Overview
      • 17.3.9.4. SWOT Analysis
      • 17.3.9.5. Strategic Overview
    • 17.3.10. Thermo Fisher Scientific Inc.
      • 17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.10.2. Product Portfolio
      • 17.3.10.3. Financial Overview
      • 17.3.10.4. SWOT Analysis
      • 17.3.10.5. Strategic Overview
    • 17.3.11. MaxCyte
      • 17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.11.2. Product Portfolio
      • 17.3.11.3. Financial Overview
      • 17.3.11.4. SWOT Analysis
      • 17.3.11.5. Strategic Overview
    • 17.3.12. Fresenius Medical Care AG & Co. KGaA
      • 17.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.12.2. Product Portfolio
      • 17.3.12.3. Financial Overview
      • 17.3.12.4. SWOT Analysis
      • 17.3.12.5. Strategic Overview

List of Tables

  • Table 01: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
  • Table 02: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Cell Therapy, 2017-2031
  • Table 03: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Allogeneic, 2017-2031
  • Table 04: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Autologous, 2017-2031
  • Table 05: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Gene Therapy, 2017-2031
  • Table 06: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Gene Therapy, 2017-2031
  • Table 07: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Viral Vector, 2017-2031
  • Table 08: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Non-viral Vector, 2017-2031
  • Table 09: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 10: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 11: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 12: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 13: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 14: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 15: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
  • Table 16: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Cell Therapy, 2017-2031
  • Table 17: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Allogeneic, 2017-2031
  • Table 18: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Autologous, 2017-2031
  • Table 19: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Gene Therapy, 2017-2031
  • Table 20: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Viral Vector, 2017-2031
  • Table 21: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Non-viral Vector, 2017-2031
  • Table 22: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 23: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Equipment, 2017-2031
  • Table 24: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 25: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 26: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 27: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 28: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
  • Table 29: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Cell Therapy, 2017-2031
  • Table 30: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Allogeneic, 2017-2031
  • Table 31: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Autologous, 2017-2031
  • Table 32: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Gene Therapy, 2017-2031
  • Table 33: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Viral Vector, 2017-2031
  • Table 34: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Non-viral Vector, 2017-2031
  • Table 35: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 36: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Equipment, 2017-2031
  • Table 37: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 38: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 39: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 40: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 41: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
  • Table 42: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Cell Therapy, 2017-2031
  • Table 43: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Allogeneic, 2017-2031
  • Table 44: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Autologous, 2017-2031
  • Table 45: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Gene Therapy, 2017-2031
  • Table 46: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Viral Vector, 2017-2031
  • Table 47: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Non-viral Vector, 2017-2031
  • Table 48: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 49: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Equipment, 2017-2031
  • Table 50: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 51: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 52: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 53: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 54: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
  • Table 55: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Cell Therapy, 2017-2031
  • Table 56: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Allogeneic, 2017-2031
  • Table 57: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Autologous, 2017-2031
  • Table 58: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Gene Therapy, 2017-2031
  • Table 59: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Viral Vector, 2017-2031
  • Table 60: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Non-viral Vector, 2017-2031
  • Table 61: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 62: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Equipment, 2017-2031
  • Table 63: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 64: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 65: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 66: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 67: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
  • Table 68: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Cell Therapy, 2017-2031
  • Table 69: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Allogeneic, 2017-2031
  • Table 70: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Autologous, 2017-2031
  • Table 71: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Gene Therapy, 2017-2031
  • Table 72: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Viral Vector, 2017-2031
  • Table 73: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Non-viral Vector, 2017-2031
  • Table 74: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 75: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Equipment, 2017-2031
  • Table 76: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 77: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 78: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, by End-user, 2017-2031

List of Figures

  • Figure 01: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Cell and Gene Therapy Manufacturing Market Value Share, by Therapy Type, 2022
  • Figure 03: Global Cell and Gene Therapy Manufacturing Market Value Share, by Product Type, 2022
  • Figure 04: Global Cell and Gene Therapy Manufacturing Market Value Share, by Indication, 2022
  • Figure 05: Global Cell and Gene Therapy Manufacturing Market Value Share, by Technology, 2022
  • Figure 06: Global Cell and Gene Therapy Manufacturing Market Value Share, by End-user, 2022
  • Figure 07: Global Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Therapy Type, 2022 and 2031
  • Figure 08: Global Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 09: Global Cell and Gene Therapy Manufacturing Market Revenue (US$ Mn), by Cell Therapy, 2017-2031
  • Figure 10: Global Cell and Gene Therapy Manufacturing Market Revenue (US$ Mn), by Gene Therapy, 2017-2031
  • Figure 11: Global Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 12: Global Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 13: Global Cell and Gene Therapy Manufacturing Market Revenue (US$ Mn), by Consumables, 2017-2031
  • Figure 14: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn), by Viral Vector Production, 2017-2031
  • Figure 15: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn), by Others, 2017-2031
  • Figure 16: Global Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 17: Global Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Technology 2023-2031
  • Figure 18: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn), by Cell Culture & Expansion, 2017-2031
  • Figure 19: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn), by Viral Vector Production, 2017-2031
  • Figure 20: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn), by Irreversible Cell Sorting & Purification, 2017-2031
  • Figure 21: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn), by Gene Editing, 2017-2031
  • Figure 22: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn), by Others, 2017-2031
  • Figure 23: Global Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 24: Global Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, Indication, 2023-2031
  • Figure 25: Global Cell and Gene Therapy Manufacturing Market Revenue (US$ Mn), by Oncology, 2017-2031
  • Figure 26: Global Cell and Gene Therapy Manufacturing Market Revenue (US$ Mn), by Cardiovascular Disorders, 2017-2031
  • Figure 27: Global Cell and Gene Therapy Manufacturing Market Revenue (US$ Mn), by Orthopedic Disease, 2017-2031
  • Figure 28: Global Cell and Gene Therapy Manufacturing Market Revenue (US$ Mn), by Infectious Disease, 2017-2031
  • Figure 29: Global Cell and Gene Therapy Manufacturing Market Value (US$ Mn), by Others, 2017-2031
  • Figure 30: Global Cell and Gene Therapy Manufacturing Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 31: Global Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 32: Global Cell and Gene Therapy Manufacturing Market Revenue (US$ Mn), by Pharmaceutical & Biotechnology Companies, 2017-2031
  • Figure 33: Global Cell and Gene Therapy Manufacturing Market Revenue (US$ Mn), by Contract Manufacturing Organizations (CMOs), 2017-2031
  • Figure 34: Global Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 35: Global Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 36: North America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 37: North America Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 38: North America Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 39: North America Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Therapy Type, 2022 and 2031
  • Figure 40: North America Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 41: North America Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 42: North America Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 43: North America Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 44: North America Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Technology 2023-2031
  • Figure 45: North America Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 46: North America Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, Indication, 2023-2031
  • Figure 47: North America Cell and Gene Therapy Manufacturing Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 48: North America Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 49: Europe Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 50: Europe Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 51: Europe Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 52: Europe Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Therapy Type, 2022 and 2031
  • Figure 53: Europe Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 54: Europe Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 55: Europe Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 56: Europe Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 57: Europe Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Technology 2023-2031
  • Figure 58: Europe Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 59: Europe Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, Indication, 2023-2031
  • Figure 60: Europe Cell and Gene Therapy Manufacturing Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 61: Europe Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 62: Asia Pacific Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 63: Asia Pacific Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 64: Asia Pacific Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 65: Asia Pacific Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Therapy Type, 2022 and 2031
  • Figure 66: Asia Pacific Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 67: Asia Pacific Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 68: Asia Pacific Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 69: Asia Pacific Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 70: Asia Pacific Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Technology 2023-2031
  • Figure 71: Asia Pacific Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 72: Asia Pacific Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, Indication, 2023-2031
  • Figure 73: Asia Pacific Cell and Gene Therapy Manufacturing Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 74: Asia Pacific Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 75: Latin America Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 76: Latin America Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 77: Latin America Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 78: Latin America Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Therapy Type, 2022 and 2031
  • Figure 79: Latin America Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 80: Latin America Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 81: Latin America Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 82: Latin America Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 83: Latin America Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Technology 2023-2031
  • Figure 84: Latin America Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 85: Latin America Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, Indication, 2023-2031
  • Figure 86: Latin America Cell and Gene Therapy Manufacturing Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 87: Latin America Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 88: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 89: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 90: Middle East & Africa Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 91: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Therapy Type, 2022 and 2031
  • Figure 92: Middle East & Africa Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 93: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Product Type, 2022 and 2031
  • Figure 94: Middle East & Africa Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Product Type, 2023-2031
  • Figure 95: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 96: Middle East & Africa Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by Technology 2023-2031
  • Figure 97: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 98: Middle East & Africa Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, Indication, 2023-2031
  • Figure 99: Middle East & Africa Cell and Gene Therapy Manufacturing Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 100: Middle East & Africa Cell and Gene Therapy Manufacturing Market Attractiveness Analysis, by End-user, 2023-2031